Shots: The P-I trial involves assessing MSB-0221 (ShA9) or vehicle applied topically on forearm skin in 54 adults with staphylococcus aureus-positive AD for 1week The expression of mRNA for psmα was inhibited from S. aureus isolated from all participants while the correlation was observed within 7days b/w improvement in local eczema severity and killing of […]Read More
Tags : P-I study
Shots: The P-I study assesses the PK/PD, safety, tolerability of SB16 (denosumab) vs Prolia in 168 healthy male volunteers for osteoporosis. The study will be 3 arms study that involves dosing with SB16 either the EU or US-sourced Prolia The proposed biosimilar references Amgen’s Prolia which was approved in 2010 for osteoporosis with a high […]Read More
Shots: The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK, PD, and immunogenicity The JHL1266 is proved to be a milestone and an initiative in bringing safe, effective, and high-quality biologics JHL1266 is a mAb targeting RANKL works by inhibition of developed […]Read More
Shots: :Stosohth:ththShots: The company reported the dosing of a first healthy volunteer in a P-I study of TD-0903 and anticipates that TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to ARDS Earlier, Theravance has received approval to initiate the P-I study for assessing safety, tolerability and pharmacokinetics of […]Read More
Shots: The P-I study involved assessing of [Fam-] trastuzumab deruxtecan (5.4, 6.4 mg/kg) in 46 patients with heavily pretreated HER2 low expressing metastatic breast cancer P-I study results: ORR (44.2 %, 47.4%); disease control rate (79.1%, 81.6%); mDOR (9.4mos., 11.0 mos.); mPFS (7.6 mos., 7.9 mos.) [Fam-] Trastuzumab deruxtecan (DS-8201) is a HER2 targeting antibody […]Read More